Curaleaf Holdings Inc. (T:CURA*CA)
Business Focus: Recreational Pharmaceuticals
| Sector: Healthcare | Industry: Pharmaceuticals |
| Company Contact | |
| Address: | 420 Lexington Avenue NEW YORK NY 10170 |
| Tel: | N/A |
| Website: | https://ir.curaleaf.com |
| IR: | See website |
| Key People | ||
| Boris Jordan Executive Chairman of the Board | Matt Darin President, Chief Executive Officer | Joseph F. Lusardi Executive Vice Chairman of the Board |
| Edward Kremer Chief Financial Officer | Tyneeha Rivers Chief People Officer | Camilo Lyon Chief Investment Officer |
| James Shorris Chief Compliance Officer | Peter Laurence Clateman Chief Legal Officer | Mitch Hara Chief Strategy Officer |
| Business Overview |
| Curaleaf Holdings, Inc. is an international provider of consumer products in cannabis. The Company and its brands, including Curaleaf, Select, and Grassroots provide service, product selection and accessibility across the medical and adult-use markets. It operates in approximately 17 states and owns and operates 147 dispensaries and 21 cultivation sites with a focus on states, including Arizona, Florida, Illinois, Massachusetts, New Jersey, New York and Pennsylvania. Curaleaf International is an integrated cannabis company in Europe with a supply and distribution network throughout the European market. It also offers Can4Med, a pharmaceutical wholesaler specializing in cannabinoid medications in Poland. Curaleaf is the national retail dispensary brand in the United States and a mainstream cannabis brand available in multiple states and product formats: vape oils and concentrates, flower, pre rolls and flower pod, topical lotions, capsules and tinctures, mints and lozenges and edibles. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, Curaleaf Holdings Inc revenues increased 6% to $1.35B. Net loss before extraordinary items decreased 11% to $229.8M. Revenues reflect Management fee income increase of 21% to $5.9M. Lower net loss reflects Loss on impairment decrease of 19% to $67.1M (expense), Share-based compensation decrease of 29% to $20M (expense), Other income - Balancing value increase from $1.8M (expense) to $4.6M (income). |
| Employees: | 5,650 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $5,535M as of Dec 31, 2023 |
| Annual revenue (TTM): | $1,840M as of Dec 31, 2023 |
| EBITDA (TTM): | $326.21M as of Dec 31, 2023 |
| Net annual income (TTM): | -$313.95M as of Dec 31, 2023 |
| Free cash flow (TTM): | $6.77M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | $1,202M as of Dec 31, 2023 |
| Shares outstanding: | 738,399,651 as of Apr 23, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.